MetaCap

Apyx Medical (APYX) vs PolyPid (PYPD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

PolyPid (PYPD) has outperformed Apyx Medical (APYX) over the past year, gaining 42.9% versus a loss of 17.8%. Over five years, APYX leads with a -82.1% price change compared with -97.8% for PYPD. PolyPid is the larger company by market cap ($99.5 million vs $99.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APYX-17.77%PYPD+42.86%
+74%+26%-22%
Oct 8, 20251 yearOct 8, 2026
APYX-82.84%PYPD-97.84%
+28%-38%-105%
Oct 4, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APYX versus PYPD key metrics
MetricAPYXPYPD
Share price$2.36$4.90
Market cap$99.41M$99.53M
1-day change-7.45%-1.01%
YTD return-32.57%+12.90%
1-year return-17.77%+42.86%
5-year return-82.05%-97.83%
EPS (TTM)$-0.20$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$5.08$5.73
52-week low$2.32$3.06
Distance from 52-week high-53.54%-14.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+175.42%+139.80%
Average volume127.72K176.73K
Shares outstanding42.12M20.31M
Employees20569
SectorHealthcareHealthcare
IndustryMedical DevicesBiotechnology

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PYPD has outperformed APYX by 60.6 percentage points over the past year.

About Apyx Medical

APYX stock →

Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM).

Healthcare · Medical Devices · 205 employees

About PolyPid

PYPD stock →

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.

Healthcare · Biotechnology · 69 employees

APYX vs PYPD FAQ

Which is bigger, Apyx Medical or PolyPid?

PolyPid (PYPD) is larger, with a market capitalization of $99.53M compared with $99.41M for Apyx Medical (APYX).

Which stock has performed better over the past year, APYX or PYPD?

PYPD returned +42.86% over the past 12 months, compared with -17.77% for APYX (price return, excluding dividends). Past performance does not predict future results.

Are Apyx Medical and PolyPid in the same industry?

Both are in the Healthcare sector, but in different industries: Medical Devices for Apyx Medical and Biotechnology for PolyPid.

More comparisons